**Addendum to:**

**UKHSA Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD), v15.0 GOV-18720**

This document provides an addendum to the [UKHSA LAIV PGD v15.0 GOV-18720,](https://www.gov.uk/government/publications/live-attenuated-influenza-vaccine-patient-group-direction-pgd-template) valid from 1 September 2025 to 1 April 2026.

In the section for ‘Name, strength and formulation of drug’, on page 13, the formula of the active strains has been updated below to align with the current SPC (21 July 2025) published on 23 July 2025.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Name, strength and formulation of drug, Page 13**  Live attenuated influenza vaccine nasal spray suspension (0.2ml):  Fluenz® nasal spray suspension, each 0.2ml dose contains:  Reassortant influenza virus (live attenuated) of the following three strains:   |  |  | | --- | --- | | A/ Victoria/4897/2022 (H1N1)pdm09 - like strain  (A/ Norway/31694/2022, MEDI 369815) | 107.0±0.5 FFU | |  |  | | A/Croatia/10136RV/2023 (H3N2) - like strain  (A/Perth/722/2024, MEDI 392611) | 107.0±0.5 FFU | |  |  | | B/ Austria/1359417/2021 - like strain  (B/ Austria/1359417/2021, MEDI 355292) | 107.0±0.5 FFU |   For the full details of the formulation see the [SPC.](https://www.medicines.org.uk/emc/product/15790/smpc)  The vaccine may contain traces of the following substances: egg proteins (e.g. ovalbumin) and gentamicin. The maximum amount of ovalbumin is less than 0.024 micrograms per 0.2 ml dose (0.12 micrograms per ml), see section 4.3 of the [SPC](https://www.medicines.org.uk/emc/product/15790/smpc). |
| **Background**  The LAIV PGD v15.0 GOV-18720 was published on 1st July 2025, as per national flu immunisation programme plan 2025 to 2026 programme timelines. The PGD had a final check on 30th June 2025 before publishing and it aligned with the Fluenz® SPC dated 6 June 2025 which was available on the EMC site at the time. Since the publication of the PGD, the SPC has gone through an update on 21 July 2025 to the ‘Qualitative and quantative composition’ section has been updated with the formula of the active strains. The updated SPC was published on the EMC on 23 July 2025.  The addendum has been provided to the PGD to inform of the updated active strains. |

**UKHSA approval and ratification**

This addendum is approved by the following health professionals on behalf of UKHSA:

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Name** | **Signature** | **Date** |
| **Pharmacist**  (Lead Author) | Suki Hunjunt  Lead Pharmacist Immunisation Programmes, UKHSA |  | 6 August 2025 |
| **Doctor** | Alex Allen  Consultant Epidemiologist  Chief Medical Advisor, UKHSA  Deputising for  Jamie Lopez-Bernal  Consultant Epidemiologist  Chief Medical Advisor, UKHSA |  | 6 August 2025 |
| **Registered Nurse**  (Chair of Expert Panel) | Greta Hayward  Consultant Midwife for Immunisation Programmes, UKHSA |  | 6 August 2025 |

This addendum has been approved by the PGD Expert Panel ([Appendix 1](#Appendix1)) and UKHSA PGD Working Group and ratified by the Medicines Governance Committee.

**Organisational authorisations**

[INSERT AUTHORISING BODY NAME] authorises the continued use of Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD), v15.0 GOV-18720 with this addendum by the services or providers listed below

|  |  |  |  |
| --- | --- | --- | --- |
| **Organisational approval (legal requirement)** | | | |
| **Role** | **Name** | **Sign** | **Date** |
| For instance, NHS England Governance Lead, Medical Director | **[** | **[** | **[** |

**Appendix 1**

**UKHSA Live attenuated influenza vaccine nasal spray suspension (LAIV) Patient Group Direction (PGD) Expert Panel**

|  |  |
| --- | --- |
| Nicholas Aigbogun | Consultant in Communicable Disease Control, Yorkshire and Humber Health Protection Team, UKHSA |
| Jessica Baldasera | Health Protection Practitioner, North East Health Protection Team  Regions Directorate, UKHSA |
| Helen Beynon | Clinical Advisor, Immunisation Clinical Advice Response Service (CARS), NHS England London |
| Alison Campbell | Screening and Immunisation Coordinator, Public Health Commissioning  NHS England (NHS England) Midlands |
| Naveen Dosanjh | Senior Clinical Advisor – Vaccinations, NHS England |
| Helen Eley | Lead Immunisation Nurse Specialist, Immunisation Programmes, UKHSA |
| Jane Freeguard | Deputy Director of Vaccination – Medicines and Pharmacy  NHS England |
| Rosie Furner | Advanced Specialist Pharmacist - Medicines Governance, Specialist Pharmacist Services (SPS) |
| Ed Gardner | Advanced Paramedic Practitioner/Emergency Care Practitioner, Medicines Manager, Proactive Care Lead |
| Shilan Ghafoor | Medicines Governance Lead Pharmacist, UKHSA |
| Elizabeth Luckett | Senior Screening and Immunisation Manager, Screening and Immunisation Team – Kent and Medway, NHS England South Eastt |
| Briony Mason | Vaccination Manager, Professional Midwifery Advocate, Vaccination and Screening, NHS England, West Midlands |
| Vanessa MacGregor | Consultant in Communicable Disease Control, East Midlands Health Protection Team, UKHSA |
| Tushar Shah | Lead Pharmacy Adviser, NHS England London |